RLF-100™ (aviptadil) The Story of Relief Therapeutics Holding AG (OTCMKTS: RLFTF)

9
5931

Relief Therapeutics Holding AG (OTCMKTS: RLFTF) is an exciting story in small caps that has been making big moves up the charts in recent months as its coronavirus therapeutic RLF-100 (aviptadil) continues to prove effective in the fight against coronavirus.

Relief and its partner NeuroRx, Inc., recently announced topline efficacy data from patients treated with RLF-100™ (aviptadil) under the U.S. FDA Expanded Access Protocol authorization for respiratory failure related to critical COVID-19.  RLF-100™ therapy associated with a 9-fold increased probability of survival and recovery from respiratory failure in an open-label, prospective study. Top-line data from randomized, placebo-controlled Phase 2b/3 trial expected this quarter

Relief Therapeutics Holding AG (OTCMKTS: RLFTF) is a Swiss Company that was founded by former Merck executives  (Serono division) whose objective is to provide patients with therapeutic relief in serious diseases with high unmet medical need. The Company’s team is working diligently to rapidly develop RLF-100™ for the benefit of COVID-19 patients. Here you will find latest news, upcoming events and interviews. Relief Therapeutics Holding AG is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on the OTCQB under the symbol RLFTF.

Relief lead product is RLF-100™ (aviptadil) a formulation of Vasoactive Intestinal Polypeptide (VIP) that was developed based on Prof. Sami Said’s original work at Stony Brook University, for which Stony Brook was awarded an FDA Orphan Drug Designation in 2001. VIP is known to be highly concentrated in the lungs, where it inhibits coronavirus replication, blocks the formation of inflammatory cytokines, prevents cell death, and upregulates the production of surfactant. FDA has now granted IND authorization for intravenous and inhaled delivery of RLF-100™ for the treatment of COVID-19 and awarded Fast Track designation. RLF-100™ is being investigated in two placebo-controlled US Phase 2b/3 clinical trials in respiratory deficiency due to COVID-19. Since July 2020, more than 150 patients with Critical COVID-19 and Respiratory Failure have been treated with RLF-100™ under FDA-approved protocols.

For the Inside Sccop on RLFTF subscribe below by email.

Sign Up now for our 100% FREE Penny Stock Newsletter

On October 13 Relief and its partner NeuroRx, Inc., announced topline results from 45 patients assessed in an open-label prospective study where 21 patients admitted to an intensive care unit (ICU) with critical COVID-19 and respiratory failure were treated with RLF-100™(aviptadil) and compared to 24 control patients treated in the same setting. All patients had severe comorbidities that rendered them ineligible for the ongoing randomized controlled phase 2b/3 trial being conducted to ascertain safety and efficacy of RLF-100™, and all patients were deteriorating despite treatment with approved therapies for COVID-19.

Overall, 81% of RLF-100™-treated patients survived beyond 60 days, compared to 17% of control patients. Patients treated with RLF-100™ demonstrated a 9-fold increased probability of survival and recovery from respiratory failure, with a high degree of statistical significance. Statistical analysis was performed by Prof. Phil Lavin, FASA, FRAPS of the Boston Biostatistical Research Foundation.

Jihad Georges Youssef, MD, section chief of General Academic Pulmonary Medicine at the Houston Methodist Hospital, who serves as the study’s principal investigator at Houston Methodist and also serves as national co-chair for the ongoing randomized controlled trial stated: “We are encouraged by these initial results in highly comorbid patients with COVID-19 respiratory failure, and we are pleased that the majority of these patients have returned safely to their families. We look forward to the upcoming results from the randomized, double-blind, prospective trial in less severely comorbid patients for confirmation of these results,”

RLFTF is the darling of small caps that has been making big moves up the charts in recent months as its coronavirus therapeutic RLF-100 (aviptadil) continues to prove effective in the fight against coronavirus. Relief and its partner NeuroRx, Inc., recently announced topline efficacy data from patients treated with RLF-100™ (aviptadil) under the U.S. FDA Expanded Access Protocol authorization for respiratory failure related to critical COVID-19.  RLF-100™ therapy associated with a 9-fold increased probability of survival and recovery from respiratory failure in an open-label, prospective study. Investors are looking forward to Top-line data from the randomized, placebo-controlled Phase 2b/3.

For the Inside Sccoop on RLFTF subscribe below by email.

Sign Up now for our 100% FREE Penny Stock Newsletter

9 COMMENTS

  1. It has not been approved yet because there are many interest involved in it that maybe FDA officials are involved. Trump and his henchmen are investing so much money on a vaccine that Aviptadil is being sidelined until a vaccine comes out and get the riches and leave the crums for aviotadil. All this is politics and moneywise interest. FDA don’t care about people.

    • you clearly have no clue what you’re talking about. Therapeutics are the desired result because, particularly with a virus like Covid-19, which can change from year to year, a vaccine is a temporary fix. A therapeutic addresses the symptoms that the virus causes. If you negate the symptoms, then it won’t matter if the virus changes. Stop thinking everything is political. Perhaps your ignorance is what makes you so angry. Educate yourself. Otherwise, you’re your worse than some snowflake victim. You’re a victim of your own ignorance.

  2. NeuroRx and Relief Therapeutics announce continuation of RLF-100™ trial for treatment of COVID-19 Respiratory Failure: Trial is on track to complete enrollment in 2020

Leave a Reply to alejandro ibarra Cancel reply

Please enter your comment!
Please enter your name here